# Assessing Risk Indicators in Clinical Practice with Joint Models of Longitudinal and Time-to-Event Data

#### Eleni-Rosalina Andrinopoulou

Department of Biostatistics, Erasmus Medical Center

e.andrinopoulou@erasmusmc.nl

Center for Clinical & Translational Science & Training, University of Cincinnati September 21th

#### **Outline**



- **▶ Introduction to Joint Models**
- > Recent Applications in Joint Models
- **⊳ Individualized Predictions**



#### **Introduction to Joint Models**

#### Introduction to Joint Models



• Often in clinical studies multiple outcomes are collected

- Type of data
  - > Longitudinal responses

#### Motivation - Data set 1





- 312 patients with primary **biliary cirrhosis**, a rare autoimmune liver disease, at Mayo Clinic
  - Dependent Patients were 50 years and older, 88% females and 50% D-peniciles

  - ▶ Longitudinal responses: serum bilirubin and serum cholesterol in mg/dl
  - ▷ Time-to-event response: time-to-death (45%)

#### Motivation - Data set 1 (con't)







#### Motivation - Data set 2




- 286 patients who received **human tissue valve in aortic position** in Erasmus University Medical Center (Department of Cardio-Thoracic Surgery)
  - Patients were 16 years and older
  - Echo examinations scheduled at 6 months and 1 year postoperatively and biennially thereafter

  - ▷ Time-to-event response: time-to-death/reoperation (54%)

# Motivation - Data set 2 (con't)





#### Motivation - Data set 3




- 1016 patients with **cystic fibrosis (CF)** in the US Cystic Fibrosis Foundation Patient Registry
  - Data recorded during childhood and adolescence (ages: 6-21 years) between January 1, 2003, and December 31, 2015

  - $\triangleright$  Time-to-event response: time-to-first exacerbation (70%)

# Motivation - Data set 3 (con't)





#### **Research Questions**



- How can we utilize all available longitudinal measurements?
- How can we better predict the survival outcomes?

How can use all available information?



• Special features should be taken into account

#### Longitudinal data

- > Correlation between measurements obtained from the same patients
- ▷ Biological variation of the outcome
- □ Unbalanced datasets

#### Survival data

▷ Censored data (partial information for the event times)

#### **Jointly**

> Association between all outcomes



- Frequently used analysis

Mixed-effects models for the longitudinal outcomes

Cox models for the time-to-event outcomes

Naive joint analysis

Cox model using the last observation


Cox model using the mean or the slope of the repeated covariate

Time-dependent Cox model




- Time-dependent Cox models are suitable only for **exogenous** covariates, not got **endogenous** 
  - $\triangleright$  A time-varying covariate is **exogenous** if its value at any time point t is not affected by an event occurring at an earlier time point s < t (period of the year, environmental variables)
  - On the other hand all covariates measured on the patient (e.g., biomarkers) are endogenous











• Let  $y_i$  represent the repeated measurements of an outcome for the i-th patient,  $i=1,\ldots,n$ 

#### Mixed-effects model:

$$y_i(t) = x_i^\top(t)\beta + z_i^\top(t)b_i + \epsilon_i(t) = \eta_i(t) + \epsilon_i(t), \quad b_i \sim N(0, D) \text{ and } \epsilon_i(t) \sim N(0, \Sigma_i)$$

#### where

- $\triangleright x_i^{\top}(t)\beta$  denotes the fixed part
- $\triangleright z_i^{\top}(t)b_i$  denotes the random part



• Let  $T_i$  denote the observed failure time for the i-th patient and  $\delta = 0, 1$  the event indicator


#### Cox model:

$$h_i(t) = h_0(t) \exp\{\gamma^{\top} \omega_i + \alpha \eta_i(t)\},$$

#### where

- $\triangleright \gamma^{\top} \omega_i$  denotes the baseline covariates with their coefficients
- $riangleright \eta_i(t)$  denotes the value of the time-dependent covariate at time t
- hd lpha measures the association between the longitudinal outcome at time t and the hazard for an event at the same time point







### **Recent Applications in Joint Models**

#### **Shrinkage Approach**



Motivated by the biliary cirrhosis data:

- Longitudinal responses:
  - > serum bilirubin
  - > serum cholesterol
- Time-to-event response:
  - time-to-death
     time-to-death
     include the state of the

Andrinopoulou, E. R. and Rizopoulos, D. (2016). Bayesian shrinkage approach for a joint model of longitudinal and SURVIVAL OUTCOMES ASSUMING DIFFERENT ASSOCIATION STRUCTURES. STATISTICS IN MEDICINE, 35(26), 4813-4823.



ullet In the standard joint model we assume that the underlying value of the longitudinal biomarker is associated with the survival outcome at a time point t

Is that option always correct?



- Inappropriate modelling of time-dependent covariates may result in surprising results
- Example: Cavender et al. (1992, J Am. Coll. Cardiol) conducted an analysis to test the effect of cigarette smoking on survival of patients who underwent coronary artery surgery
  - by the estimated effect of current cigarette smoking was positive on survival although not significant (i.e. patient who smoked had higher probability of survival)



We need to carefully consider which longitudinal outcomes and which functional forms we will include

• Let's investigate that . . .




Different parameterizations Let us assume k = 1, ..., K longitudinal outcomes

$$M_{1}: h_{i}(t) = h_{0}(t) \exp\{\gamma^{\top} w_{i} + \sum_{k=1}^{K} \alpha_{k1} \eta_{ik}(t)\},$$


$$M_{2}: h_{i}(t) = h_{0}(t) \exp\{\gamma^{\top} w_{i} + \sum_{k=1}^{K} \alpha_{k2} \eta'_{ik}(t)\},$$

$$M_{3}: h_{i}(t) = h_{0}(t) \exp\{\gamma^{\top} w_{i} + \sum_{k=1}^{K} \alpha_{k3} \int_{0}^{t} \eta_{ik}(s) ds\}$$
:
















#### Extension of the standard JM

$$h_i(t) = h_0(t) \exp \left[ \gamma^{\top} w_i + \sum_{k=1}^K \sum_{j=1}^J f_j \{ \eta_{ik}(t), \alpha_{kj} \} \right],$$

#### where

 $\triangleright i = 1, \dots, n$  represents the patient,

 $\triangleright k = 1, \dots, K$  represents the longitudinal outcome

 $\triangleright j = 1, \dots, J$  represents the parameterization



For every longitudinal outcome which features are more predictive for survival?



High dimensional model



Variable selection problem



For every longitudinal outcome which features are more predictive for survival?



High dimensional model



Variable selection problem



**Penalties** 



- We employed a Bayesian approach and used Markov chain Monte Carlo (MCMC) methods to estimate the parameters of the proposed joint model
  - ▷ Shrinkage priors for the association parametes
  - > Priors that give a high probability of being near 0
    - Bayesian lasso
    - Bayesian ridge
    - Horseshoe




#### Analysis:

- Longitudinal submodels (Serum bilirubin and Serum cholesterol):
- Survival submodel (Time-to-death):
  - > underlying value, slope and the area under the curve for serum bilirubin and serum cholesterol
  - □ age and gender



#### Results:



#### **Time-Varying Effects**



Motivated by the heart data:

- Longitudinal response:
  - > aortic gradient
- Time-to-event response:
  - ⊳ time-todeath/reoperation

Andrinopoulou, E. R., Eilers, P. H., Takkenberg, J. J. and Rizopoulos, D. (2017). Improved dynamic predictions from JOINT MODELS OF LONGITUDINAL AND SURVIVAL DATA WITH TIME-VARYING EFFECTS USING P-SPLINES. BIOMETRICS, DOI: 10.1111/BIOM.12814.


# Time-Varying Effects (cont'd)



- Standard joint models assume a constant regression coefficient for the effect of the covariates.
  - > when treatment is initiated, the strength of the association between the longitudinal and survival outcomes may also change



#### Proportional hazard assumption - Time dependent Cox model





A time-varying coefficient joint model



Specifically,

$$h_i(t) = h_0(t) \exp[\gamma^{\top} w_i + f_j \{ \lambda_j(t), \eta_i(t) \}],$$

where

- $w_i$  is a vector of baseline covariates with a corresponding vector of regression coefficients  $\gamma$
- $f_i\{\lambda_i(t_i), \eta_i(t)\}$  is the form of association (j = 1, ..., J) between the longitudinal and the survival outcomes  $\rightarrow$  underlying value, slope or area under the curve



• We consider estimation of the function  $\lambda_j(t)$  using the regression P-spline method, where

$$\lambda_{j}(t) = \sum_{\ell=1}^{L} \alpha_{j\ell} B_{\ell}(t, \nu),$$

#### where

- $\alpha_{j\ell}$  is a set of parameters that capture the strength of association between the longitudinal and survival outcomes
- $B_\ell(t_i, 
  u)$  denotes the q-th basis function of a B-spline with knots  $u_1, \dots, 
  u_Q$
- The idea behind the P-spline method is to assume a high number of knots and penalize the coefficients to tackle the problem of the large number or parameters



 We employ a Bayesian approach and use Markov chain Monte Carlo (MCMC) methods to estimate the parameters of the proposed joint model

• The penalty from the frequentist penalized likelihood translates into a prior distribution




#### Analysis:

- Longitudinal submodel (Aortic gradient):
- **Survival submodel** (Time-to-death/reoperation):
  - > value and slope of aortic gradient
  - ▷ gender



Results:



#### **Latent Class Joint Model**




### Motivated by the CF data:

- Longitudinal response:
  - $\triangleright$  **FEV**<sub>1</sub>
- Time-to-event response:
  - b time-to-first exacerbation

Andrinopoulou, E.R., Nasserinejad, K., Szczesniak, R. and Rizopoulos, D. (2018). Integrating Latent Classes in the Bayesian Shared Parameter Joint Model of Longitudinal and Survival Outcomes. arXiv preprint arXiv:1802.10015.



- Standard joint models assume homoscedasticity
  - $\triangleright$  Latent sup-populations  $\Rightarrow$  **FEV**<sub>1</sub>





- Special features
  - ▷ Time-to-first exacerbation is associated with FEV₁



### Joint modeling of longitudinal and survival data

- > shared parameter joint models



- Special features
  - ▷ Time-to-first exacerbation is associated with FEV₁



#### Joint modeling of longitudinal and survival data

- > shared parameter joint models
  - + quantify the strength of the association
  - does not allow for latent sub-populations



- Special features
  - ▷ Time-to-first exacerbation is associated with FEV₁



### Joint modeling of longitudinal and survival data

- > shared parameter joint models
- - + postulates the existence of sub-populations
  - does not quantify the strength of the association



#### Combine



shared parameter joint model

joint latent class model



#### Longitudinal data

 $\triangleright$  Let  $y_i$  represent the repeated measurements of an outcome for the i-th patient,  $i=1,\ldots,n$ 

#### Mixed-effects submodel:

$$y_{ic}(t) = x_i^{\top}(t)\beta_c + z_i^{\top}(t)b_{ic} + \epsilon_i(t) = \eta_{ic}(t) + \epsilon_i(t), \quad b_{ic} \sim N(0, D_c) \text{ and } \epsilon_i(t) \sim N(0, \Sigma_i)$$

#### where

- $\triangleright x_i^{\top}(t)\beta_c$  denotes the fixed part
- $\triangleright z_i^{\top}(t)b_{ic}$  denotes the random part
- $\triangleright c$  indicates the class  $c = 1, \ldots, C$



#### Survival data

 $\triangleright$  Let  $T_i$  denote the observed failure time for the *i*-th patient and  $\delta = 0, 1$  the event indicator

#### Survival submodel:

$$h_{ic}(t) = h_{0c}(t) \exp[\gamma_c^{\top} \omega_i + \alpha_c \eta_{ic}(t)],$$

where

 $\triangleright \omega_i$  denotes the baseline covariates

 $\triangleright \eta_{ic}(t)$  denotes the longitudinal outcome

 $\triangleright \alpha_c$  association parameter



• Problem:

> What is the optimal number of classes

• Solution: Commonly used

▶ BIC: Frequentist

DIC: Bayesian



- Problem:
  - > What is the optimal number of classes
- Solution: Commonly used
  - ▶ BIC: Frequentist
  - DIC: Bayesian → time-consuming



- Problem:
  - > What is the optimal number of classes
- Solution: Rousseau and Mengersen (RM), Journal of Royal Statistical Society, 2011



- Problem:
  - **▶** What is the optimal number of classes
- Solution: Rousseau and Mengersen (RM), Journal of Royal Statistical Society, 2011
  - Step 2: obtain the number of non-empty classes at each iteration as:

$$c_{opt} = C - \sum_{c=1}^{C} I(\frac{N_c}{N} \le \psi),$$

where  $N_c$  is the number of observations in class c, N is the total number of observations and  $\psi$  is a predefined number



- Problem:
  - > What is the optimal number of classes
- Solution: Rousseau and Mengersen (RM), Journal of Royal Statistical Society, 2011
  - Step 3: calculate the posterior mode of the non-empty classes



- Problem:
  - > What is the optimal number of classes
- Solution: Rousseau and Mengersen (RM), Journal of Royal Statistical Society, 2011
  - Step 4: fit the model with the optimal number of classes



 We employed a Bayesian approach and used Markov chain Monte Carlo (MCMC) methods to estimate the parameters of the proposed joint model. For the class we assume,

$$\pi_{ic} \sim Dirichlet(A_c)$$

$$\triangleright A_c = A_1, \dots, A_C$$

$$\triangleright A_c < d/2$$

 $\triangleright d$  number of class-specific parameters



### Analysis:

- Longitudinal submodels (FEV<sub>1</sub>):
- **Survival submodel** (Time-to-first exacerbation):
  - $\triangleright$  value of  $FEV_1$
  - ⊳ gender




• Optimal number of classes

RM approach: 6 classes

- $\triangleright$  cut off  $(\psi)$  8%  $\rightarrow$  3 classes
- $\triangleright$  cut off  $(\psi)$  10%  $\rightarrow$  3 classes
- $\triangleright$  cut off  $(\psi)$  15%  $\rightarrow$  3 classes




Results: Less sick patients (females/males)






Results: More sick patients (females/males)





Results:





### **Individualized Predictions**

### **Clinical Decision Making**



ullet Guide clinical decision making o use **complete** biomarker information

### **Dynamic nature:**

different progression per patient progression changes over time within the same patient


Repeated measurements provide better predictions

### Clinical Decision Making (cont'd)




Subject-specific risk predictions based on the joint model ightarrow useful tool























































































































































Andrinopoulou, E. R., Rizopoulos, D., Takkenberg, J. J. and Lesaffre, E. (2015). Combined dynamic predictions using JOINT MODELS OF TWO LONGITUDINAL OUTCOMES AND COMPETING RISK DATA. STATISTICAL METHODS IN MEDICAL RESEARCH. 6(4):1787-1801.

Andrinopoulou, E. R., Rizopoulos, D., Geleijnse, M. L., Lesaffre, E., Bogers, A. J. and Takkenberg, J. J. (2015). DYNAMIC PREDICTION OF OUTCOME FOR PATIENTS WITH SEVERE AORTIC STENOSIS: APPLICATION OF JOINT MODELS FOR LONGITUDINAL AND TIME-TO-EVENT DATA. BMC CARDIOVASCULAR DISORDERS, 15(1), 1.

#### **Discussion**



• Joint models - popular framework

Software

▷ JM, JMbayes: R

⊳ joineR, joineRML: **R** 

▷ stjm: Stata

▷ JMFit: SAS

#### Thank you!



Any questions?